CClinicalTrials.gg
Active, not recruitingNCT06431334Updated Oct 6, 2026

Protein Requirements Amongst Male Masters-Level Athletes Following a Cycling Exercise Bout as Determined by the Indicator Amino Acid Oxidation Technique

An interventional study of Amino Acid Intake in Healthy, Increased Metabolic Requirements and Dietary Reference Intakes, sponsored by McGill University. Active, not recruiting at 1 site in Canada. Open to male participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by McGill University · Not applicable, Interventional, and Basic science

Updated Oct 6, 2026Now Active, not recruitingNow Completed+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
65 Years and older
Sex
Male
01

Study summary

Masters level cyclists are a population above the age of 35 years who frequently participate in prolonged as well as heavy-volume training. Like most endurance-trained athletes, a greater recommended dietary allowance (RDA) for protein of 1.2-1.4 g/kg/bw is suggested.

Dietary protein intake is vital for maximizing the benefits of training and ensuring optimal recovery. Dietary recommendations traditionally have been determined through nitrogen balance techniques, however, recent research indicates how this method is potentially underestimating protein requirements. Therefore, there is a need to reassess current dietary recommendations in order to meet the demands of physical activity for highly active populations.

Recent efforts to understand protein requirements during rest and following exercise have been completed using the indicator amino acid technique (IAAO). This non-invasive method is reported to provide a robust measure of protein requirements. However, there is limited work in older (≥60 years) active populations.

The purpose of this study is to measure the protein requirements in master cyclists, following an endurance training session, using the non-invasive IAAO technique.

02

Conditions studied

  • Healthy
  • Increased Metabolic Requirements
  • Dietary Reference Intakes
03

In context

Lead sponsor

McGill University is the lead sponsor of 244 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18.5\< BMI \<35 kg/m\^2
  • Overtly healthy masters level cyclists ≥65 years
  • Masters level cyclist training (>4 days per week; \~100 km per week)
  • Body mass stable over previous 6-months
  • Availability for multiple metabolic trials (\~7 trials)
  • Ability to travel to and from laboratory facility

Exclusion criteria

Exclusion Criteria:

  • Recent history of weight loss or weight gain (>5% body weight)
  • Uncontrolled hypertension
  • ≥2 chronic diseases (e.g. diabetes, osteoporosis, dyslipidemia)
  • Acute illness that could affect protein metabolism (HIV, renal dysfunction, influenza)
  • Currently using anti-inflammatory medications
  • Inability to adhere to study protocol (i.e., alcohol, caffeine, dietary restrictions)
  • Regular tobacco user
  • Illicit drug use
  • Habitually ingesting ≥3 g/kg/bw
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Masters Level Cyclists

    Participants are to be randomly assigned varying levels of amino acid intakes ranging between 0.2 to 2.8 g/kg/d

    Dietary Supplement: Amino Acid Intake

Interventions

  • Dietary supplementAmino Acid Intake

    Amino acid intakes will vary between 0.2 to 2.8 g/kg/d

06

What researchers measure

Primary outcomes

  1. 13CO2 Excretion

    Measured by continuous-flow isotope ratio mass spectrometry

    Time frame: 7-weeks

Secondary outcomes

  1. L[13C]phenylalanine Oxidation

    Measured by gas chromatography-mass spectrometry

    Time frame: 7-weeks

07

Study locations

1 site
  • McGill University
    Montreal, Quebec H3A 0G4, Canada
08

Updates

2 registry updates since Sep 25, 2026
Status
Recruiting→Completed→Active, not recruiting
changed Sep 30, 2026 · changed Oct 6, 2026
Primary completion
Jun 2026→Oct 8, 2026
moved 2 times, Sep 30, 2026 – Oct 6, 2026
Study completion
Jun 2026→Oct 8, 2026
moved 2 times, Sep 30, 2026 – Oct 6, 2026
Show all 2 updates
  1. Oct 6, 2026
    Completed→Active, not recruiting
    Primary completion Sep 27, 2026→Oct 8, 2026
    Study completion Sep 27, 2026→Oct 8, 2026
    + 1 other change: verification date
  2. Sep 30, 2026
    Recruiting→Completed
    Primary completion Jun 2026→Sep 27, 2026 (now actual)
    Study completion Jun 2026→Sep 27, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06431334
Lead sponsor
McGill University
Responsible party
Tyler Churchward-Venne (Associate Professor, McGill University) — Principal investigator
First posted
May 28, 2024
Start date
Jun 21, 2024
Primary completion
Oct 8, 2026 (estimated)
Completion
Oct 8, 2026 (estimated)
Last update
Oct 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion